RE: Patients, Patience + Patents30 Nov 2022 12:03
Seeing as c4 receives 2x recommended dose of doxorubicin, directly to the tumor, if any of the patients tumors had almost or completely disappeared, would it be ethical to still dose these patients in another cohort, or would they need to recruit new ?